[go: up one dir, main page]

FI970918A0 - Föreningar och förfarande för behandling av cancer - Google Patents

Föreningar och förfarande för behandling av cancer

Info

Publication number
FI970918A0
FI970918A0 FI970918A FI970918A FI970918A0 FI 970918 A0 FI970918 A0 FI 970918A0 FI 970918 A FI970918 A FI 970918A FI 970918 A FI970918 A FI 970918A FI 970918 A0 FI970918 A0 FI 970918A0
Authority
FI
Finland
Prior art keywords
cancer
compounds
treatment
methods
Prior art date
Application number
FI970918A
Other languages
English (en)
Finnish (fi)
Other versions
FI970918A (sv
Inventor
Chung K Chu
Yung-Chi Cheng
Original Assignee
Univ Georgia
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/301,298 external-priority patent/US5817667A/en
Application filed by Univ Georgia, Univ Yale filed Critical Univ Georgia
Publication of FI970918A0 publication Critical patent/FI970918A0/sv
Publication of FI970918A publication Critical patent/FI970918A/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
FI970918A 1994-09-06 1997-03-04 Föreningar och förfarande för behandling av cancer FI970918A (sv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/301,298 US5817667A (en) 1991-04-17 1994-09-06 Compounds and methods for the treatment of cancer
US39063395A 1995-02-17 1995-02-17
PCT/US1995/011464 WO1996007413A1 (en) 1994-09-06 1995-09-05 Compounds and methods for the treatment of cancer

Publications (2)

Publication Number Publication Date
FI970918A0 true FI970918A0 (sv) 1997-03-04
FI970918A FI970918A (sv) 1997-05-02

Family

ID=26972285

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970918A FI970918A (sv) 1994-09-06 1997-03-04 Föreningar och förfarande för behandling av cancer

Country Status (31)

Country Link
US (3) US6063787A (sv)
EP (2) EP0781136B1 (sv)
JP (1) JP3979662B2 (sv)
KR (1) KR100374477B1 (sv)
CN (3) CN1111409C (sv)
AP (1) AP783A (sv)
AT (1) ATE267015T1 (sv)
AU (1) AU704977B2 (sv)
BG (1) BG63122B1 (sv)
BR (1) BR9508886A (sv)
CA (1) CA2199117C (sv)
CZ (1) CZ297873B6 (sv)
DE (1) DE69533066T2 (sv)
DK (1) DK0781136T3 (sv)
ES (1) ES2219666T3 (sv)
FI (1) FI970918A (sv)
HU (1) HUT77172A (sv)
IL (1) IL115156A (sv)
IS (1) IS2011B (sv)
MY (1) MY121548A (sv)
NO (1) NO313268B1 (sv)
NZ (1) NZ335013A (sv)
OA (1) OA10473A (sv)
PL (2) PL189288B1 (sv)
PT (1) PT781136E (sv)
RO (1) RO118748B1 (sv)
RU (1) RU2168995C2 (sv)
SI (1) SI0781136T1 (sv)
SK (1) SK284564B6 (sv)
WO (1) WO1996007413A1 (sv)
ZA (1) ZA957483B (sv)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US5728575A (en) * 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
US6495553B1 (en) 1997-08-08 2002-12-17 Newbiotics, Inc. Methods and compositions for overcoming resistance to biologic and chemotherapy
JP2002500880A (ja) 1998-01-23 2002-01-15 ニューバイオティックス インコーポレイテッド 酵素に触媒される治療剤
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
DK1058686T3 (da) 1998-02-25 2007-03-05 Univ Emory 2'-fluornukleosider
NZ529882A (en) * 1999-03-29 2005-05-27 Shire Biochem Inc Methods of treating leukemia
AU2004201676B2 (en) * 1999-03-29 2006-03-09 University Of Georgia Research Foundation, Inc. Methods of treating leukemia
US6653318B1 (en) 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
EP1214074B1 (en) 1999-09-24 2004-06-16 Shire Biochem Inc. Dioxolane nucleoside analogs for the treatment or prevention of viral infection
EP1225899A2 (en) 1999-11-04 2002-07-31 Virochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
EP1600451A3 (en) 1999-11-12 2008-09-10 Pharmasset, Inc. Synthesis of 2'-deoxy-l-nucleosides
CN100376570C (zh) * 2000-10-13 2008-03-26 希拉生物化学股份有限公司 改善胞间传输的二氧戊环类似物
US7138388B2 (en) 2001-01-19 2006-11-21 Celmed Oncology (Usa), Inc. Methods to treat autoimmune and inflammatory conditions
WO2002076472A2 (en) * 2001-03-23 2002-10-03 Shire Biochem Inc. Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
CN1744902B (zh) * 2001-03-23 2010-05-26 希拉加拿大股份有限公司 治疗癌症的药物组合
WO2002078678A2 (en) * 2001-03-30 2002-10-10 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
AU2002336864B2 (en) * 2001-11-02 2006-08-17 Shire Biochem Inc. Pharmaceutical compositions for the treatment of leukemia comprising dioxolane nucleosides analogs
US7858662B2 (en) * 2001-11-19 2010-12-28 Medigene Ag Medicament for the treatment of viral skin and tumour diseases
CA2462070C (en) 2002-06-21 2012-03-20 Lg Electronics Inc. Recording medium having data structure for managing reproduction of video data recorded thereon
AU2003241198B2 (en) 2002-06-21 2009-09-03 Lg Electronics Inc. Recording medium having data structure for managing reproduction of video data recorded thereon
KR20040000290A (ko) 2002-06-24 2004-01-03 엘지전자 주식회사 고밀도 광디스크의 멀티 경로 데이터 스트림 관리방법
AU2003241205B2 (en) 2002-06-24 2009-03-26 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple title video data recorded thereon and recording and reproducing methods and apparatuses
CN1565031B (zh) 2002-06-28 2010-09-29 Lg电子株式会社 一种用于管理多个路径数据的记录和再现的方法及装置
KR100665439B1 (ko) 2002-10-14 2007-01-04 엘지전자 주식회사 기록된 복수의 오디오 스트림의 재생을 관리하기 위한데이터 구조를 갖는 기록 매체, 그에 따른 기록 및 재생방법 및 장치
JP4903998B2 (ja) 2002-10-15 2012-03-28 エルジー エレクトロニクス インコーポレイティド 記録された複数のグラフィックストリームの再生を管理するためのデータ構造を有する記録媒体、それによる記録及び再生方法及び装置
US7720356B2 (en) 2002-11-12 2010-05-18 Lg Electronics Inc Recording medium having data structure for managing reproduction of multiple reproduction path video data recorded thereon and recording and reproducing methods and apparatuses
US7664372B2 (en) 2002-11-20 2010-02-16 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple component data recorded thereon and recording and reproducing methods and apparatuses
US7693394B2 (en) 2003-02-26 2010-04-06 Lg Electronics Inc. Recording medium having data structure for managing reproduction of data streams recorded thereon and recording and reproducing methods and apparatuses
US7809775B2 (en) 2003-02-27 2010-10-05 Lg Electronics, Inc. Recording medium having data structure for managing playback control recorded thereon and recording and reproducing methods and apparatuses
KR101119108B1 (ko) 2003-02-28 2012-06-12 엘지전자 주식회사 기록되는 비디오 데이터의 랜덤/셔플 재생을 관리하기 위한데이터 구조를 갖는 기록 매체와 그에 따른 기록 및 재생방법 및 장치
US7620301B2 (en) 2003-04-04 2009-11-17 Lg Electronics Inc. System and method for resuming playback
EP1684780B1 (en) 2003-10-09 2012-07-25 MediGene AG The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin
EP1890537B1 (en) 2005-06-07 2012-08-08 Yale University Methods of treating cancer and other conditions or disease states using lfmau and ldt
EP1968595A4 (en) * 2005-12-02 2014-05-21 Univ Yale METHOD FOR THE TREATMENT OF CANCER AND OTHER CONDITIONS OR DISEASES WITH L-CYTOSINE NUCLEOSIDE ANALOGUE
NO324263B1 (no) * 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
CN101534835B (zh) * 2006-09-01 2012-05-30 佐治亚大学研究基金会 用于癌症的L-OddC的前药
CN103720693A (zh) * 2011-11-15 2014-04-16 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
CN102406649A (zh) * 2011-11-15 2012-04-11 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
CA3045228C (en) * 2016-12-28 2024-01-02 Transgene Sa Oncolytic viruses and therapeutic molecules
SG10201708886RA (en) * 2017-10-30 2019-05-30 Xylonix Ip Holdings Pte Ltd α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
FI87783C (sv) * 1985-05-15 1993-02-25 Wellcome Found Förfarande för framställning av terapeutiskt användbara 2',3'-dideoxin ukleosider
JPS62501712A (ja) * 1985-08-26 1987-07-09 アメリカ合衆国 ２′、３′―ジデオキシイノシン、２′，３′―ジデオキシグアノシンまたは２′，３′―ジデオキシアデノシンを含有する抗ｈｔｌｖ―３／ｌａｖ剤
US4879277A (en) * 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
DK167377B1 (da) * 1985-09-17 1993-10-25 Wellcome Found 3'-azidopyrimidinnucleosider eller farmaceutisk acceptable salte eller estere deraf til anvendelse ved behandling af eller profylakse for en human retrovirusinfektion
IN164556B (sv) * 1986-03-06 1989-04-08 Takeda Chemical Industries Ltd
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
FR2601385B1 (fr) * 1986-07-09 1989-09-29 Sucre Rech & Dev Procede de preparation a partir de saccharose d'un melange de sucres a haute teneur en isomaltose par voie enzymatique et produits obtenus
US4963533A (en) * 1986-10-24 1990-10-16 Stichting Rega Vzw (Rega) Therapeutic application of dideoxycytidinene
US5215971A (en) * 1986-12-19 1993-06-01 Medivir Ab Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides
ATE108183T1 (de) * 1987-03-24 1994-07-15 Nycomed Imaging As 2',3'-dideoxyribofuranoxid-derivate.
US5185437A (en) * 1987-04-09 1993-02-09 Burroughs Wellcome Co. Therapeutic nucleosides
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US4900828A (en) * 1988-05-12 1990-02-13 Hoffmann-Laroche Inc. Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine
SE8802687D0 (sv) * 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
AU618436B2 (en) * 1988-12-19 1991-12-19 Wellcome Foundation Limited, The Antiviral cytosine and guanine derivatives
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US5059690A (en) * 1990-03-01 1991-10-22 E. R. Squibb & Sons, Inc. Purinyl tetrahydrofurans
US5071983A (en) * 1989-10-06 1991-12-10 Burroughs Wellcome Co. Therapeutic nucleosides
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
IE904378A1 (en) * 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines
US5700937A (en) * 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5527782A (en) * 1990-03-13 1996-06-18 Acic (Canada) Inc. 5-halo-2,3'-O-cyclocytidines
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
AU9125991A (en) * 1990-12-05 1992-07-08 University Of Georgia Research Foundation, Inc., The Enantiomerically pure beta -l-(-)-1,3-oxathiolane nucleosides
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
NZ250842A (en) * 1991-02-22 1996-03-26 Univ Emory Resolution of a racemic mixture of nucleoside enantiomers such as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (ftc)
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
IL101144A (en) * 1991-03-06 1996-09-12 Wellcome Found Pharmaceutical compositions containing 1-(2-hydroxymethyl)-1,3-oxathiolan-5-fluorocytosine and derivatives thereof for the treatment of hepatitis b virus infections
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
AU1596495A (en) * 1993-12-30 1995-07-17 Genta Incorporated Improved process for the purification of oligomers
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5971983A (en) * 1997-05-09 1999-10-26 The Regents Of The University Of California Tissue ablation device and method of use

Also Published As

Publication number Publication date
DE69533066T2 (de) 2005-06-02
US6063787A (en) 2000-05-16
US20080171758A1 (en) 2008-07-17
WO1996007413A1 (en) 1996-03-14
RU2168995C2 (ru) 2001-06-20
CA2199117A1 (en) 1996-03-14
NO971015L (no) 1997-03-05
CA2199117C (en) 2006-04-11
AU704977B2 (en) 1999-05-13
NO313268B1 (no) 2002-09-09
IL115156A0 (en) 1995-12-31
NO971015D0 (no) 1997-03-05
JPH10506385A (ja) 1998-06-23
FI970918A (sv) 1997-05-02
AP783A (en) 1999-11-17
MY121548A (en) 2006-02-28
KR970705393A (ko) 1997-10-09
SK284564B6 (sk) 2005-06-02
IS2011B (is) 2005-05-13
CZ63397A3 (en) 1997-07-16
BG63122B1 (en) 2001-04-30
ES2219666T3 (es) 2004-12-01
EP1468687A1 (en) 2004-10-20
EP0781136B1 (en) 2004-05-19
IS4434A (is) 1997-03-04
CN1251680C (zh) 2006-04-19
KR100374477B1 (ko) 2003-06-19
HUT77172A (hu) 1998-03-02
US8076347B2 (en) 2011-12-13
SI0781136T1 (en) 2004-08-31
AU3586295A (en) 1996-03-27
EP0781136A1 (en) 1997-07-02
PL318971A1 (en) 1997-07-21
US20050261320A1 (en) 2005-11-24
OA10473A (en) 2002-04-08
ATE267015T1 (de) 2004-06-15
JP3979662B2 (ja) 2007-09-19
PL188359B1 (pl) 2005-01-31
CN1827108A (zh) 2006-09-06
CN1448142A (zh) 2003-10-15
EP0781136A4 (en) 1999-06-23
BG101284A (en) 1998-03-31
CN1111409C (zh) 2003-06-18
US7262213B2 (en) 2007-08-28
NZ335013A (en) 2000-07-28
AP9700939A0 (en) 1997-04-30
RO118748B1 (ro) 2003-10-30
DE69533066D1 (de) 2004-06-24
CZ297873B6 (cs) 2007-04-18
ZA957483B (en) 1997-06-06
DK0781136T3 (da) 2004-08-02
CN1160351A (zh) 1997-09-24
IL115156A (en) 2000-07-16
PT781136E (pt) 2004-09-30
SK28197A3 (en) 1997-09-10
BR9508886A (pt) 1997-12-30
PL189288B1 (pl) 2005-07-29

Similar Documents

Publication Publication Date Title
FI970918A0 (sv) Föreningar och förfarande för behandling av cancer
FI971969A (sv) Kompositioner för behandling av hemorrojder och användningsmetod
FI971568A (sv) Förfarande för behandling av resistenta tumörer
FI952926A0 (sv) Förfaranden för behandling och förebyggande av allFörfaranden för behandling och förebyggande av allergies ergies
FI954383A (sv) Förfarande för framställning av cancervacciner
FI964330A (sv) Förfarande och anordning för trapphissar
FI954119A (sv) Förfarande för behandling av fast avfall
FI962370A0 (sv) Anordning för tillverkning av tissue
FI971750A (sv) Kompositioner och behandling för multipel sclerosis
FI972245A (sv) Mesomonojodsubstituerade tetramakrocykliska föreningar samt förfarande för framställning och användning därav
FI19992807A (sv) Förfarande och arrangemang för eliminering av störning
FI972235A0 (sv) Förfarande för användning av triaryletylenderivat vid behandling och förhindrande av osteoporos
FI962976A0 (sv) Kompositioner för behandling av galukom innehållande pilokarpin och beta-spärrare
IL127739A0 (en) Retinoyloxy (substituted) alkylene butyrates useful for the treatment of cancer and other proliferative diseases
IL115320A0 (en) Retinoyloxy (substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases
NO981822L (no) Anvendelse av proteinet GAX for behandling av cancer
FI964113A0 (sv) Medicinsk sammansättning för behandling av tardiv dyskinesi och användning av densamma
FI955777A (sv) Förfarande och varusortiment för utföring av hårbehandling
FI980543A0 (fi) Spetsdragningsanordning och foerfarande foer spetsdragning av en bana
FI973367A (sv) F"rfarande och anordning f"r behandling av problemavfall
FI970098A0 (sv) Metod och förening för behandling av håravfall
FI972694A0 (sv) Nytt förfarande för framställning av sameridin
FI951441A (sv) Förfarande för framställning av 5-formylamino-pyrimidiner
FI961732A0 (sv) Förfarande och anordning för tillverkning och/elleFörfarande och anordning för tillverkning och/eller behandling av en stickning r behandling av en stickning
FI964672A0 (sv) Förfarande för behandling av säd, behandlad säd och användning därav